206874-43-3

Usage

Type of compound

Organic compound

Physical state

Colorless to pale yellow liquid

Solubility

Soluble in organic solvents

Use as a reagent

Commonly used in organic synthesis

Function

Protecting group for alcohols and amines, allowing for selective reactions in the presence of other functional groups

Use as a precursor

In the synthesis of pharmaceuticals and agrochemicals

Safety

Handle with caution and follow proper safety protocols.

Upstream product

• 52022-77-2 2-(3-nitrophenyl)ethanol 
• 124-63-0 methanesulfonyl chloride 
• 10268-12-9 methyl 3-nitrophenylacetate 
• 621-50-1 (3-nitrophenyl)acetonitrile 
• 3958-57-4 1-bromomethyl-3-nitrobenzene 
• 1877-73-2 3-nitro-benzeneacetic acid 

Downstream Products

• 176091-70-6 C₁₁H₁₆N₂O₂ 
• 932405-32-8 N,N-diethyl-2-(3-nitrophenyl)ethanamine 
• 1308256-30-5 methyl(3-nitrophenethyl)sulfane 
• 1308256-31-6 3-(2-(methylthio)ethyl)aniline 
• 1308256-32-7 2,2,2-trifluoro-N-(3-(2-(methylthio)ethyl)phenyl)acetamide 
• 1308256-33-8 2,2,2-trifluoro-N-(3-(2-(methylsulfonyl)ethyl)phenyl)acetamide 
• 1308256-34-9 2-(2-(methylsulfonyl)ethyl)-4-(2,2,2-trifluoroacetamido)benzenesulfonic acid 
• 1308256-12-3 C₁₁H₁₁ClF₃NO₅S₂ 
• 1308256-35-0 C₁₈H₁₈BF₃N₂O₇S₂ 
• 1308256-36-1 2-(2-(methylsulfinyl)ethyl)-4-(2,2,2-trifluoroacetamido)benzene-1-sulfonyl chloride 
• 1308256-37-2 2,2,2-trifluoro-N-(4-(N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)sulfamoyl)-3-(2-(methylsulfinyl)ethyl)phenyl)acetamide 
• 943720-98-7 tert-butyl 4-(3-nitrophenethyl)piperazine-1-carboxylate 
• 1027357-84-1 C₁₂H₁₆N₂O₄S 
• 1023277-64-6 C₁₃H₁₉N₃O₂ 

Relevant academic research and scientific papers

FGFR inhibitor preparation method

The invention relates to a synthesis method of an FGFR inhibitor (R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazoline-2-amine represented by a formula (I), and belongs to the field of organic synthesis. The me

BORON-CONTAINING SMALL MOLECULES

This invention relates to 6-substituted benzoxaborole compounds of the following formula and their use for treating bacterial infections.

Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl) -2-imidazolidinone (GSK163090), a potent, selective, and orally active 5-HT 1A/B/D receptor antagonist

In an effort to identify selective drug like pan-antagonists of the 5-HT1 autoreceptors, studies were conducted to elaborate a previously reported dual acting 5-HT1 antagonist/SSRI structure. A novel series of compounds was identifie

6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING

Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE

The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form thereof, wherein A, Y, Z, R101 and R200 are described in the specification.

DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS

Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS

Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

Bicyclic-substituted amines having cyclic-substituted monocyclic substituents

Compounds of formula (I) wherein R1 or R2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L2 and L3, to a heteroaromatic core, and X, X′, Y, Y′, Z, Z′, R1,

Bicyclic-substituted amines having cyclic-substituted monocyclic substituents

Compounds of formula (I) wherein R1 or R2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L2 and L3, to a heteroaromatic core, and X, X′, Y, Y′, Z, Z′, R1,